ABBV-712 / AbbVie - LARVOL DELTA

ABBV-712-induced cardiac pathology in rats is related to off-target-driven acute vasodilation, tachycardia, and increased cardiac contractility. (PubMed, Toxicol Sci) - "Telemetry-instrumented rats were administered ABBV-712 with or without atenolol to investigate effects of co-dosing on hemodynamic parameters and cardiac pathology. These effects were unrelated to TYK2 inhibition. This report is an example of a cross-functional mechanistic investigation into the pharmacologic cause of an identified cardiovascular toxicity."

Journal • Preclinical • Cardiovascular • Myocardial Infarction • TYK2

Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712. (PubMed, J Med Chem) - "Successful targeting of the TYK2 pseudokinase domain as a strategy to achieve isoform selectivity was recently exemplified with deucravacitinib. Described herein is the optimization of selective TYK2 inhibitors targeting the pseudokinase domain, resulting in the discovery of the clinical candidate ABBV-712 (21)."

Journal • Immunology • IL12A • IL23A • JAK1 • JAK2 • JAK3 • TYK2